3 research outputs found
Realidade virtual no controlo da dor na criança / jovem submetidos a procedimentos dolorosos em contexto hospitalar : uma revisão scoping
Enquadramento: A realidade virtual é uma intervenção não farmacológica que utiliza uma
tecnologia imersiva de distração, otimizando a capacidade de o utente pediátrico experienciar
a dor durante a realização de procedimentos médicos invasivos e dolorosos.
Objetivo: Mapear as evidências científicas existentes sobre a utilização da realidade virtual
como intervenção não farmacológica no controlo da dor na criança/jovem em procedimentos
dolorosos, em contexto hospitalar.
Métodos: Revisão scoping, tendo por base a metodologia proposta pelo Joanna Briggs
Institute. Pesquisaram-se estudos entre fevereiro e março de 2023, nos idiomas português,
inglês, espanhol, italiano e francês, independentemente do ano de publicação, nas bases de
dados PubMed, LILACS, B-ON, CINAHL Complete, MEDLINE Complete, Nursing & Allied
Health Collection: Comprehensive, Cochrane Central Register of Controlled Trials e
MedicLatina e também no RCAAP. Dos 738 estudos selecionados inicialmente, foram
incluídos 10 estudos na revisão. A seleção dos estudos, a extração e síntese dos dados foram
realizados por dois revisores independentes.
Resultados: Os estudos incluídos publicados entre 2018 e 2023, revelam que as evidências
que sustentam a utilização da realidade virtual no controlo da dor na criança/jovem
submetidos a procedimentos dolorosos em contexto hospitalar, são promissoras e os
resultados são relevantes para a sensibilização das equipas de saúde. A sua utilização
evidencia ser eficaz na redução da intensidade da dor, permitindo uma melhor tolerância à
dor e desta forma adquire-se uma melhor colaboração da criança e jovem e por vezes uma
redução do tempo efetivo para a realização dos procedimentos.
Conclusão: Os resultados apresentados demonstram que a realidade virtual tem o potencial
de ser uma alternativa não farmacológica segura, eficaz, divertida e valiosa para controlo da
dor, contribuindo para a implementação de práticas de enfermagem de excelência. A
relevância do tema evidencia a necessidade de pesquisas, sobre a utilização da realidade
virtual mais imersiva para controlo da dor na área pediátrica durante a realização de
procedimentos dolorosos e impulsiona a sua utilização nos diversos contextos hospitalares,
com a elaboração de protocolos devidamente fundamentados.
Palavras-chave: realidade virtual; criança; adolescente; pediatria; dor; controlo da dor; dor,
procedimento; hospitalização; hospitalar; doentes internados.Abstract
Background: Virtual reality is a non-pharmacological intervention that uses an immersive
distraction technology, optimizing the pediatric patient's ability to experience pain during
invasive and painful medical procedures.
Objective: To map the existing scientific evidence on the use of virtual reality as a nonpharmacological
intervention in pain control in children/young people in painful procedures, in
a hospital setting.
Methods: Scoping review, based on the methodology proposed by the Joanna Briggs Institute.
Studies were searched between February and March 2023, in Portuguese, English, Spanish,
Italian and French, regardless of the year of publication, in the PubMed, LILACS, B-ON,
CINAHL Complete, MEDLINE Complete, Nursing & Allied Health Collection: Comprehensive,
Cochrane Central Register of Controlled Trials and MedicLatina databases and also in
RCAAP. Of the 738 studies initially screened, 10 studies were included in the review. Study
selection, data extraction and synthesis were performed by two independent reviewers.
Results: The included studies published between 2018 and 2023, reveal that the evidence
supporting the use of virtual reality in pain control in children/young people undergoing painful
procedures in a hospital setting, is promising and the results are relevant for the awareness of
health teams. Its use proves to be effective in reducing the intensity of pain, allowing a better
tolerance to pain and thus acquiring a better collaboration of the child and young person and
sometimes a reduction in the effective time to perform the procedures.
Conclusion: The results presented show that virtual reality has the potential to be a safe,
effective, fun and valuable non-pharmacological alternative for pain control, contributing to the
implementation of excellent nursing practices. The relevance of the topic highlights the need
for research on the use of more immersive virtual reality for pain management in the pediatric
area during the performance of painful procedures and encourages its use in various hospital
settings, with the elaboration of duly substantiated protocols.
Keywords: virtual reality; child; adolescent; pediatrics; pain; pain management; pain,
procedural; hospitalization; hospitals; inpatients
Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells
Pancreatic cancer is one of the most lethal cancers, with an extremely poor prognosis. The development of more effective therapies is thus imperative. Natural origin compounds isolated from Plectranthus genus, such as parvifloron D (PvD), have cytotoxic and antiproliferative activity against human tumour cells. However, PvD is a very low water-soluble compound, being nanotechnology a promising alternative strategy to solve this problem. Therefore, the aim of this study was to optimize a nanosystem for preferential delivery of PvD to pancreatic tumour cells. Albumin nanoparticles (BSA NPs) were produced through a desolvation method. Glucose cross-linking and bioactive functionalization profiles of BSA platform were elucidated and analysed using static lattice atomistic simulations in vacuum. Using the optimized methodology, PvD was encapsulated (yield higher than 80%) while NPs were characterized in terms of size (100–400 nm) and morphology. Importantly, to achieve a preferential targeting to pancreatic cancer cells, erlotinib and cetuximab were attached to the PvD-loaded nanoparticle surface, and their antiproliferative effects were evaluated in BxPC3 and Panc-1 cell lines. Erlotinib conjugated NPs presented the highest antiproliferative effect toward pancreatic tumour cells. Accordingly, cell cycle analysis of the BxPC3 cell line showed marked accumulation of tumour cells in G1-phase and cell cycle arrest promoted by NPs. As a result, erlotinib conjugated PvD-loaded BSA NPs must be considered a suitable and promising carrier to deliver PvD at the tumour site, improving the treatment of pancreatic cancer